Literature DB >> 19147246

Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.

Stephen F Kry1, Mohammad Salehpour, Uwe Titt, R Allen White, Marilyn Stovall, David Followill.   

Abstract

PURPOSE: To evaluate the photon and neutron out-of-field dose equivalents from 6- and 18-MV intensity-modulated radiation therapy (IMRT) and to investigate the impact of the differences on the associated risk of induced second malignancy using a Monte Carlo model. METHODS AND MATERIALS: A Monte Carlo model created with MCNPX was used to calculate the out-of-field photon dose and neutron dose equivalent from simulated IMRT of the prostate conducted at beam energies of 6 and 18MV. The out-of-field dose equivalent was calculated at the locations of sensitive organs in an anthropomorphic phantom. Based on these doses, the risk of secondary malignancy was calculated based on organ-, gender-, and age-specific risk coefficients for a 50-year-old man.
RESULTS: The Monte Carlo model predicted much lower neutron dose equivalents than had been determined previously. Further analysis illuminated the large uncertainties in the neutron dose equivalent and demonstrated the need for better determination of this value, which plays a large role in estimating the risk of secondary malignancies. The Monte Carlo calculations found that the differences in the risk of secondary malignancies conferred by high-energy IMRT versus low-energy IMRT are minimal and insignificant, contrary to prior findings.
CONCLUSIONS: The risk of secondary malignancy associated with high-energy radiation therapy may not be as large as previously reported, and likely should not deter the use of high-energy beams. However, the large uncertainties in neutron dose equivalents at specific locations within the patient warrant further study so that the risk of secondary cancers can be estimated with greater accuracy.

Entities:  

Mesh:

Year:  2009        PMID: 19147246     DOI: 10.1016/j.radonc.2008.11.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies.

Authors:  M Hussein; S Aldridge; T Guerrero Urbano; A Nisbet
Journal:  Br J Radiol       Date:  2011-10-18       Impact factor: 3.039

2.  A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models.

Authors:  Bryan Bednarz; Basit Athar; X George Xu
Journal:  Med Phys       Date:  2010-05       Impact factor: 4.071

3.  Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans.

Authors:  Basit S Athar; Harald Paganetti
Journal:  Radiother Oncol       Date:  2010-12-13       Impact factor: 6.280

4.  Analytical model for out-of-field dose in photon craniospinal irradiation.

Authors:  Phillip J Taddei; Wassim Jalbout; Rebecca M Howell; Nabil Khater; Fady Geara; Kenneth Homann; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2013-10-08       Impact factor: 3.609

Review 5.  Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship.

Authors:  Amy Berrington de Gonzalez; Ethel Gilbert; Rochelle Curtis; Peter Inskip; Ruth Kleinerman; Lindsay Morton; Preetha Rajaraman; Mark P Little
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-24       Impact factor: 7.038

6.  Consideration of the radiation dose delivered away from the treatment field to patients in radiotherapy.

Authors:  Michael L Taylor; Tomas Kron
Journal:  J Med Phys       Date:  2011-04

7.  Dose-volume histogram comparison between static 5-field IMRT with 18-MV X-rays and helical tomotherapy with 6-MV X-rays.

Authors:  Akihiro Hayashi; Yuta Shibamoto; Yukiko Hattori; Takeshi Tamura; Michio Iwabuchi; Shinya Otsuka; Chikao Sugie; Takeshi Yanagi
Journal:  J Radiat Res       Date:  2015-01-20       Impact factor: 2.724

Review 8.  Second primary cancers after radiation for prostate cancer: a review of data from planning studies.

Authors:  Louise Murray; Ann Henry; Peter Hoskin; Frank-Andre Siebert; Jack Venselaar
Journal:  Radiat Oncol       Date:  2013-07-08       Impact factor: 3.481

9.  The effect of photon energy on intensity-modulated radiation therapy (IMRT) plans for prostate cancer.

Authors:  Wonmo Sung; Jong Min Park; Chang Heon Choi; Sung Whan Ha; Sung-Joon Ye
Journal:  Radiat Oncol J       Date:  2012-03-31

10.  Optimal tumor coverage with different beam energies by IMRT, VMAT and TOMO: Effects on patients with proximal gastric cancer.

Authors:  Sheng-Fang Huang; Jang-Chun Lin; An-Cheng Shiau; Yun-Chih Chen; Ming-Hsien Li; Jo-Ting Tsai; Wei-Hsiu Liu
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.